Recent Acquisition Augmentix Corporation was acquired by Boston Scientific in September 2018 for $500 million, indicating strong interest from major players in medical device innovation, which could open opportunities for suppliers and partners aligned with healthcare technologies.

Healthcare Focus The company specializes in device technologies that reduce side effects of radiotherapy for prostate cancer, highlighting a niche for advanced medical hardware solutions and potential collaboration with healthcare providers.

Growth Potential With an annual revenue between $10 million and $25 million and recent integration into Boston Scientific's portfolio, there is potential for rapid growth and increased demand for specialized hardware in the medical markets.

Industry Alignment Operating within the computer hardware manufacturing industry with a focus on medical applications positions Augmentix as a strategic partner for companies seeking innovative hardware solutions in healthcare technology development.

Strategic Tech Use Utilizing Apache technology and advanced hardware design, Augmentix exemplifies a company leveraging robust technical foundations, offering opportunities for tech providers and system integrators to support their infrastructure needs.